August 25, 2017
A spokesperson for Janssen, the division of Johnson & Johnson that makes etomidate, told The Washington Post the company objects to the drug’s use in an execution.
Asay’s lawyers filed an objection to the use of etomidate, but the Florida Supreme Court denied the stay request, writing “Asay failed to establish sure or very likely risks of sufficiently imminent danger or a proposed alternative that is readily available.”
Jen Moreno, a lethal injection expert at the University of California, Berkeley Law School’s death penalty clinic, told the Miami Herald it was unclear if the drug would work. “There are outstanding questions about whether it’s going to do what it needs to do during an execution,” she told the paper. “The state hasn’t provided any information about why it has selected this drug.”
Image via Flickr United States Government Work
NPR The Two-Way
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.